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Piceatannol is found in grapes, passion fruit, and Japanese knotweed. Piceatannol pretreatment sup-
presses cardiac hypertrophy induced by isoproterenol as assessed by heart weight/body weight ratio,
cross-sectional area, and expression of hypertrophic markers. The anti-hypertrophic effect of picea-
tannol in rat neonatal cardiomyocytes is the same as that in vivo. Piceatannol inhibits lentiviral-
GATA6-induced cardiomyocyte hypertrophy. Furthermore, piceatannol reduces the interaction
between GATA4 and GATA6 as well as the DNA-binding activity of endogenous GATA6 in the ANP
promoter. Our results suggest that piceatannol may be a novel therapeutic agent for the prevention
of cardiac hypertrophy.
Structured summary of protein interactions:
GATA6 physically interacts with GATA4 by anti V5 tag coimmunoprecipitation (View interaction)
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction and food components have been reported to have beneﬁcial rolesStimulated cardiomyocytes may undergo hypertrophy without
associated hyperplasia.
In response to the initial stress, cardiomyocytes show a compen-
satory reaction; under sustained stress, however, they do not re-
verse to the normal state. Cardiac hypertrophy is characterized by
an increase in heart mass, enhanced protein synthesis, highly orga-
nized sarcomeres, and reactivation of the fetal gene program [1].
In cardiac hypertrophy, cardiac-speciﬁc transcription factors
such as GATA4, GATA6, myocyte-speciﬁc enhancer factor 2C
(MEF2C), homeobox protein Nkx2-5, nuclear factor of activated
T-cells (NFAT), serum response factor (SRF), and cAMP-response
element-binding protein (CREB) are well known to regulate the
cardiac gene program [2]. To date, much evidence has been
presented on treating or preventing cardiac hypertrophy through
the development of pharmacological targets. A variety of plantsin pathological heart diseases. For example, curcumin, quercetin,
and resveratrol appear to attenuate myocardial infarction, cardiac
hypertrophy [3–5], and heart failure [6].
Piceatannol (trans-3,4,30,50-tetrahydroxystilbene), a natural ana-
logue and a metabolite of resveratrol, exists in grapes, red wine, and
passion fruit seed [7].Recently,piceatannolwas reported tohavepleio-
tropic roles in inhibiting cancer, inﬂammation, proliferation, invasion,
migration, and adipogenesis [8–10]. Piceatannol is known to be an
inhibitor of spleen tyrosine kinase (Syk), phosphoinositide 3-kinase
(PI3K), and nuclear factor-jB (NF-jB). Although evidence of a beneﬁ-
cial effect of piceatannol on heart diseases has not been reported, we
hypothesized that piceatannol would attenuate cardiac hypertrophy.
Therefore, in the present study, we examined the effects of
piceatannol on the development of cardiac hypertrophy in mice
and in rat primary cardiomyocytes.
2. Materials and methods
2.1. Reagents and antibodies
Phenylephrine (PE) and isoproterenol (ISP) were purchased
from Sigma (Sigma–Aldrich Co., USA). Piceatannol was purchased
from Future Chem (FutureChem Co., Korea).
1530 H.J. Kee et al. / FEBS Letters 588 (2014) 1529–1536Anti-Gapdh (sc-32233) and anti-SRF (sc-335) were from Santa
Cruz Biotechnology; antibody to atrial natriuretic peptide (anti-
ANP) was from Meridian (Meridian Life Science, USA); anti-GATA4
and anti-GATA6 were from Abcam (Abcam, Cambridge Science
Park in Cambridge, UK); and anti-sarcomere a-actinin (A7811)
was from Sigma.
2.2. Cell cultures
Primary cardiomyocytes from 2-day-old Sprague–Dawley rats
were prepared as described previously [11]. Brieﬂy, heart tissue
was enzymatically dissociated with collagenase and the cells were
isolated using Percoll gradients. Cells were plated on collagen-
coated culture dishes.
HEK 293 cells were obtained from the Seoul Korean Cell Line
Bank (Seoul, Korea) and were maintained in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS).
2.3. Lentiviral GATA6 production and virus infection
Construction of lentiviral GATA6 was prepared as described
previously [12]. Brieﬂy, pRRL-RRE-cPPT-CMV-PRE-SIN-mouse
GATA6 was prepared by subcloning after PCR ampliﬁcation of the
coding region of GATA6 (restriction enzyme site withMluI and NheI
from pcDNA3.1-mouse GATA6-V5/His). Lentiviral GFP was used for
the control vector and was generated as previously described.
2.4. Luciferase assay
The 2.5 kb GATA6 promoter construct was kindly provided by
Prof. Manfred Gessler, University of Würzburg, Würzburg, Ger-
many. Luciferase assays were performed as described previously
[13]. pGL3-638 ANP wild, pGL3-638 ANP proximal mutant, pGL3-
638 ANP distal mutant, pGL3-3003 ANP promoter, or 2.5 kb
GATA6 promoter and pCMV-b-galactosidase were transfected with
Lipofectamine Plus reagent (Invitrogen) or PolyFect reagent (Qia-
gen) according to the manufacturer’s instructions. The proximal
(139 to 127) and distal (297 to 286) mutants of 638 ANP
promoter were generated by site-directed mutagenesis as shown
in Fig. 4C (upper panel). The cells were incubated in serum-free
DMEM for 24 h before treatment and for an additional 24 h with
PE or piceatannol. Cell lysates were prepared and luciferase activity
was measured with a luciferase assay kit (Promega, USA).
2.5. [3H]Leucine and [3H]thymidine incorporation assay
[3H]Leucine [14] and [3H]thymidine incorporation assays [13]
were performed as described previously, respectively.
2.6. Western blot analysis
Western blots were performed as described previously [15].
Cells lysates were prepared with RIPA buffer (150 mMNaCl, 1% Tri-
ton X-100, 1% sodium deoxycholate, 50 mM tris–HCl, pH 7.5, 2 mM
EDTA, 5 mMNaF) containing protease inhibitors. Proteinswere sep-
arated by 8–12% SDS-PAGE and were then transferred to polyvinyl-
idene diﬂuoride (PVDF) membranes. The membranes were probed
with the indicated antibodies and were developed by using Immo-
bilon Western Detection Reagents (Millipore, Billerica, MA, USA).
2.7. Real-time reverse transcription-polymerase chain reaction (RT-
PCR)
Total RNA was isolated with TriZol reagent (Invitrogen Life
Technologies), and 1 lg of RNA was used for the reverse transcrip-
tion reaction with the Superscript ﬁrst-strand synthesis system forRT-PCR kit (Invitrogen Life Technologies). Quantiﬁcation of mRNA
amounts was done with the SYBR Green PCR kit (Applied Biosys-
tems, Inc). PCR was performed by using the following oligonucleo-
tide primers:
for ANP, sense, 50-GCTCGAGCAGATCGCAAAAG-30, and antisense,
50-GAGTGGGAGAGGTAAGGCCT-30; for Gapdh, sense, 50-TGCACCAC
CAACTGCTTAG-30, and antisense, 50-GATGCAGGGATGATGTTC-30.
2.8. Cell size and sarcomeric organization
Rat neonatal cardiomyocytes were plated on 8-well chambers
and ﬂuorescent immunocytochemistry was performed as de-
scribed previously [14]. After treatment with PE or piceatannol,
cells were ﬁxed, permeabilized, and visualized by staining with
Texas Red-X phalloidin or sarcomeric a-actinin antibody (1:200)
and the cell size was measured by use of NIS Elements Software
(Nicon, Japan).
2.9. Chromatin immunoprecipitation (ChIP) and immunoprecipitation
(IP)
The ChIP assay was performed by using a kit according to the
manufacturer’s protocols (Upstate Biotechnology) [16]. Brieﬂy,
rat neonatal cardiomyocytes were treated with piceatannol for
6 h. Cells were ﬁxed with 1% formaldehyde for 5–10 min.
The sonicated chromatin was immunoprecipitated with GATA6
(sc-9055x for ChIP) antibody or control goat antibody and then
recovered with protein A-agarose/salmon sperm DNA beads. The
resulting DNA was ampliﬁed by qRT-PCR using primers spanning
the GATA binding sites (504 to 81). Control region was ampli-
ﬁed by using primers without potential GATA binding site (exon1,
+21 to +178).
For immunoprecipitation, 293T cells were transfected with
pcDNA3-GATA4 and pcDNA3-GATA6-V5 by PolyFect reagent
(Qiagen). Whole rat cells lysates were incubated with V5 antibody.
Immunocomplex was pulled down using Dynabeads Protein G
(Invitrogen).
2.10. Animal models and assessment of cross-sectional area in hearts
All protocols were approved by the Animal Care and Use Com-
mittee of Chonnam National University. The adult male C57BL/6
mice (6–8 weeks old) used in the current study were purchased
from Samtako Bio Korea (Gyeonggi, Korea). Mice were divided into
three groups: vehicle-treated control, ISP-injected group, and ISP-
injected with piceatannol pretreatment (n = 11–14). Mice were
intraperitoneally pretreated with piceatannol (50 mg/kg/day) for
7 days followed by treatment with ISP (10 mg/kg/day) for 3–4 days.
To determine the cross-sectional area of cardiac myocytes, we
performed wheat germ agglutinin Alexa Fluor 488 staining
(1:200) as described previously [17].
2.11. Statistical analysis
Statistical analysis was performed with either Student’s t-test
or one-way ANOVA with a Bonferroni post hoc test with software
provided by GraphPad Prism version 5.0. Data are presented as
means ± S.E.M. A P value of <0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Piceatannol pretreatment inhibits cardiac hypertrophy in
isoproterenol-treated mice
Cell cycle progression is implicated in cardiac hypertrophy. Be-
cause piceatannol has an anti-proliferative effect, we hypothesized
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found that treatment with piceatannol and ISP simultaneously
for 10 days signiﬁcantly inhibits heart weight to body weight
(HW/BW) ratio (Fig. 1A). In another experiment, pretreatment
with piceatannol (50 mg/kg/day) suppressed the increase in the
HW/BW ratio (Fig. 1B) induced by isoproterenol (10 mg/kg daily).
Rationale for piceatannol dose used in animal experiments is based
from several studies showing a suppressive effect of ischemic
stroke [18].
As shown in Fig. 1C and D, the cross-sectional area in ISP-stim-
ulated mice pretreated with piceatannol was completely inhibited0
2
4
6
8
H
ea
rt
 W
ei
gh
t /
 B
od
y 
W
ei
gh
tA B 
G Sham                            ISP    
Sham                   ISP                IS
E 
Sh
am ISP
ISP
+P
IC
0
2
4
6
8
10
p<0.001
p<0.001(n=6~7)
co-treatment with ISP & PIC
H
ea
rt
 W
ei
gh
t 
/ B
od
y 
W
ei
gh
t
C 
anti-GAPDH 
anti-ANP
Sham ISP IS
Wheat Germ Agglutinin stainin
IHC : anti
Fig. 1. Piceatannol pretreatment attenuates cardiac hypertrophy in vivo. (A) Mice were in
(10 mg/kg per day) for 10 days. (B) Mice were intraperitoneally pretreated with vehicle
were co-administered with piceatannol and isoproterenol for 3–4 days. ISP and PIC indic
groups. (C) Cardiomyocyte size by wheat germ agglutinin staining in sham mice, ISP mi
groups as measured by cross-sectional areas. (E) Representative Western blot for ANP from
from hearts of the 3 groups. (G) Immunohistochemistry for ANP (green) from hearts. Ercompared with that in vehicle-treated ISP mice. ISP-induced
increases in protein level of ANP were abolished by pretreatment
with piceatannol (Fig. 1E and F). Moreover, piceatannol pretreat-
ment inhibited ISP-induced ANP expression in heart sections
(Fig. 1G).
3.2. Pretreatment with piceatannol inhibits PE-induced cardiomyocyte
hypertrophy
PE, an a-adrenergic agonist, is a well-known inducer of cardiac
hypertrophy. Cardiac hypertrophy is characterized by increasedSh
am ISP
ISP
 + 
PIC
0
1000
2000
3000
4000
p<0.001
p<0.001
(n=70)
C
ro
ss
 s
ec
tio
na
l a
re
a
 (a
rb
itr
ar
y 
un
it)
Sh
am ISP
ISP
+P
IC
(n=11~14)
p<0.001
p<0.05
Pretreatment with PIC
F 
                       ISP+PIC
P+PIC
D 
Sh
am ISP
ISP
+P
IC
0
1
2
3
4
p<0.01
p<0.01
R
el
at
iv
e 
AN
P 
ex
pr
es
si
on
P+PIC 
g
-ANP
traperitoneally co-treated with piceatannol (50 mg/kg body weight per day) and ISP
or piceatannol at 50 mg/kg body weight daily for 7 consecutive days and then mice
ate isoproternol and piceatannol, respectively. Heart to body weight ratios of the 3
ce, and ISP mice treated with piceatannol. (D) Quantitative histomorphometry of 3
heart protein extracts in sham, ISP, and ISP + PIC mice. (F) Relative ANP expression
rors bars in the ﬁgure indicate ± S.E.s.
1532 H.J. Kee et al. / FEBS Letters 588 (2014) 1529–1536cell size, increased protein synthesis, induction of the fetal gene
program, and promoter activity. First, to study the anti-hypertro-
phic effect of piceatannol in vitro, we measured cell size. As shown
in Fig. 2A and B, treatment of cardiomyocytes with PE increased
cell size and stress ﬁber formation, and this increase was signiﬁ-
cantly inhibited by piceatannol. To further conﬁrm the effect of
piceatannol on fetal gene expression, we performed Western blot
and qRT-PCR for ANP. We found that piceatannol reduced ANP
protein and mRNA expression levels induced by PE (Fig. 2C–E).
Furthermore, PE-stimulated [3H]leucine uptake was attenuated
by piceatannol (Fig. 2F). To further conﬁrm whether down-regula-
tion of ANP was regulated at the transcript level, we assayed the
activity of -3003 ANP promoter. As shown in Fig. 2G, PE increasedVehicle PE PE+PIC
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3.3. Piceatannol inhibits GATA6-mediated cardiac hypertrophy in
cardiomyocytes
Next, we wanted to know whether the transcription factors
GATA4 and GATA6 mediate cardiac hypertrophy. First, we exam-
ined whether GATA4 and GATA6 were induced in response to dif-
ferent stimuli in mice. As shown in Fig. 3A and B, the expression of
GATA4 protein was not changed in response to stimulation with PE
or ISP. However, GATA6 protein levels were signiﬁcantly increased
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increased the GATA6 protein expression level (Fig. 3D). We also
conﬁrmed that GATA6 protein levels were induced within 24 h
after PE treatment in cardiomyocytes (data not shown). We found
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hypertrophy through interaction with other cardiac transcription
factors. We demonstrated that GATA6 potentiated the -3003 full
ANP promoter activity with co-transfection of GATA4 in 293T cells.
However, piceatannol treatment signiﬁcantly inhibited the GATA4/
GATA6-mediated transactivation of the -3003 ANP promoter
(Fig. 4A). We also showed that GATA6 potentiated SRF-induced -
3003 ANP promoter activity and that the cooperative synergy
was attenuated by piceatannol treatment (Fig. 4B). We further
determined whether the GATA binding element is necessary in
the piceatannol-induced regulation of the ANP promoter. As shown
in Fig. 4C, piceatannol inhibited wild-type ANP promoter activity,
but failed to inhibit promoter activity when the GATA-binding ele-
ment was mutated. Next, we examined whether the activity of
GATA6 binding to the ANP promoter region was regulated by
piceatannol. As shown in Fig. 4D, piceatannol treatment reduced
GATA6 binding in the ANP promoter. We further investigated
whether the potentiation of GATA4/GATA6-mediated transactiva-
tion of the ANP promoter was attributable to binding of GATA4–
GATA6. Immunoprecipitation revealed that GATA4 physically
interacted with GATA6 in 293T cells (Fig. 4E). Treatment of picea-
tannol in 293T cells co-transfected with GATA4 and GATA6
reduced the interaction between GATA4 and GATA6 (Fig. 4F).
4. Discussion
In the present study, we demonstrated both in vivo and in vitro
that the phytochemical piceatannol inhibits cardiac hypertrophy.
Our ﬁndings are summarized in Fig. 4G. As shown, hypertrophic
stimuli such as an a- or b-adrenergic agonist induce expression
of the transcription factor GATA6 in mice and in cardiomyocytes.
GATA6 induces cardiomyocyte hypertrophy and this induction of
hypertrophy is potentiated by interaction between GATA6 and
GATA4. Pretreatment with piceatannol can inhibit the cardiac
hypertrophy. Our ﬁndings showed that piceatannol decreases
GATA6 expression induced by hypertrophic stimuli. In addition,
piceatannol inhibits cardiac hypertrophy through a reduction in
the binding activity between GATA4 and GATA6.
The transcription factors GATA4, GATA6, SRF, and MEF2 are
known to be important in regulating cardiac hypertrophy. We no-
ticed that GATA6 protein levels were increased by hypertrophic
stimuli with PE or ISP in vivo and against PE stimuli in vitro. We
examined whether GATA6 overexpression by lentiviral GATA6
infection was sufﬁcient for inducing cardiac hypertrophy. We
showed that GATA6 increased myocyte cell size and the protein
synthesis rate as well as ANP promoter activity in cultured cardio-
myocytes. Our ﬁndings are consistent with previous data indicating
that adenovirus GATA6 infection or GATA6 transgene expression in
mice is sufﬁcient to induce a hypertrophic response [19].
One possible mechanism involved in the inhibitory effect of
piceatannol on cardiac hypertrophy may be the regulation of the
transcription factors GATA4 and GATA6. First, we found that picea-
tannol decreases the protein levels of GATA6 induced by hypertro-
phic stimuli in cardiomyocytes or mice. Second, we demonstrated
that piceatannol prevents the synergistic effect of GATA4 and
GATA6. For example, interestingly, piceatannol inhibited the
potentiated transactivation of the ANP promoter in cells co-trans-
fected with GATA4 and GATA6. In addition, by use of a GATA bind-
ing mutant luciferase construct, we revealed that the GATA binding
region is required for activation of the ANP promoter. Third, we
showed that piceatannol can block the physical interaction of
GATA4 and GATA6. Consistent with our result, GATA4 was shown
to physically interact with GATA6 in postnatal cardiomyocytes
[20]. Last, we showed that piceatannol can inhibit the DNA binding
activity of the GATA binding element in the ANP promoter.In conclusion, we have elucidated that piceatannol can prevent
cardiac hypertrophy in vivo and in vitro. Indeed, our studies
showed that piceatannol inhibits the development of cardiac
hypertrophy through regulation of the expression and activity of
transcriptional factor GATA6.Disclosures
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